We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+13.99%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$7.33B
AUM Growth
+$796M
Cap. Flow
-$12M
Cap. Flow %
-0.16%
Top 10 Hldgs %
60.07%
Holding
377
New
123
Increased
61
Reduced
77
Closed
82

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$68.6M
2
ARGX icon
argenx
ARGX
+$55M
3
SNY icon
Sanofi
SNY
+$50.7M
4
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$50.5M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$42.3M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$48.6M
2
KDP icon
Keurig Dr Pepper
KDP
+$45.5M
3
INCY icon
Incyte
INCY
+$45.2M
4
UNH icon
UnitedHealth
UNH
+$37.3M
5
CPB icon
Campbell Soup
CPB
+$32M

Sector Composition

Rank Sector Weight
1 Healthcare 34.97%
2 Consumer Staples 5.35%
3 Consumer Discretionary 4.92%
4 Technology 3.86%
5 Communication Services 1.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$2.02B 27.58%
4,250,000
-250,000
-6% -$111M
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$80.9B
$1.47B 20%
7,300,000
+800,000
+12% +$143M
PTCT icon
3
PTC Therapeutics
PTCT
$6.37B
$189M 2.58%
6,864,000
+714,000
+12% +$16.3M
NBIX icon
4
Neurocrine Biosciences
NBIX
$17.7B
$138M 1.89%
1,048,000
-168,365
-14% -$19.4M
SUPN icon
5
Supernus Pharmaceuticals
SUPN
$2.68B
$135M 1.84%
4,650,000
-442,000
-9% -$11.7M
ARGX icon
6
argenx
ARGX
$57.4B
$121M 1.65%
318,000
+118,000
+59% +$55M
AUPH icon
7
Aurinia Pharmaceuticals
AUPH
$1.97B
$85.7M 1.17%
9,536,000
+3,488,000
+58% +$28.7M
DCPH
8
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$83.9M 1.15%
5,200,000
+588,000
+13% +$7.5M
GSK icon
9
GSK
GSK
$103B
$81.4M 1.11%
2,196,000
+1,911,000
+671% +$68.6M
SWAV
10
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$81.2M 1.11%
426,057
+267,055
+168% +$50.5M
JAZZ icon
11
Jazz Pharmaceuticals
JAZZ
$15.9B
$80.1M 1.09%
651,626
+338,882
+108% +$42.3M
AGIO icon
12
Agios Pharmaceuticals
AGIO
$2.16B
$78.5M 1.07%
3,524,000
+200,000
+6% +$4.48M
FRPT icon
13
Freshpet
FRPT
$2.83B
$69.7M 0.95%
803,258
-11,471
-1% -$786K
GOOGL icon
14
Alphabet (Google) Class A
GOOGL
$3.91T
$69.3M 0.95%
496,000
+26,425
+6% +$3.55M
AMZN icon
15
Amazon
AMZN
$2.5T
$68.9M 0.94%
453,292
-68,077
-13% -$9.54M
NVRO
16
DELISTED
NEVRO CORP.
NVRO
$68.3M 0.93%
3,176,000
-280,000
-8% -$5M
XRAY icon
17
Dentsply Sirona
XRAY
$2.59B
$67.5M 0.92%
1,896,000
+68,195
+4% +$2.16M
TVTX icon
18
Travere Therapeutics
TVTX
$5.33B
$66.4M 0.91%
7,384,000
-116,000
-2% -$845K
IRWD icon
19
Ironwood Pharmaceuticals
IRWD
$611M
$65.2M 0.89%
5,700,000
+2,244,000
+65% +$22.2M
MDGL icon
20
CALL
Madrigal Pharmaceuticals
MDGL
$12.6B
$64.8M 0.88%
280,000
+120,000
+75% +$21M
BHVN icon
21
Biohaven
BHVN
$2.16B
$64.2M 0.88%
1,500,000
-536,000
-26% -$16.7M
MSFT icon
22
Microsoft
MSFT
$2.84T
$60.9M 0.83%
161,993
+28,494
+21% +$10.1M
IMVT icon
23
Immunovant
IMVT
$8.09B
$60.5M 0.83%
1,436,000
+400,123
+39% +$14.7M
EXAS
24
DELISTED
Exact Sciences
EXAS
$57.1M 0.78%
771,821
+60,301
+8% +$3.95M
REGN icon
25
Regeneron Pharmaceuticals
REGN
$68.8B
$52.7M 0.72%
60,000
-14,998
-20% -$12.4M
1
2 3 4 5

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
DWM
Diversify Wealth Management Sandy, Utah $5.61B AUM 19.63% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
AIM
Alphinity Investment Management Sydney, Australia $5.68B AUM 26.72% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return

Armistice Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Armistice Capital held 377 positions worth $7.33B, up 12% from $6.53B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Armistice Capital's Q4 2023 filing shows 123 new, 61 increased, 77 reduced and 82 closed positions. Its largest new stake was Sanofi: 1,036,000 shares worth $51.5M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $48.6M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 34% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

  • Armistice Capital's largest Q4 2023 buy was Sanofi: 1,036,000 shares worth $51.5M.
  • Armistice Capital added most to GSK in Q4 2023, an estimated $68.6M increase.
  • Armistice Capital's biggest Q4 2023 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $48.6M.
  • Armistice Capital fully exited Keurig Dr Pepper in Q4 2023, selling an estimated $45.5M.
  • Armistice Capital's ten largest holdings make up 60% of its $7.33B portfolio in Q4 2023.
  • Armistice Capital opened 123 new positions and closed 82 in Q4 2023.
  • Armistice Capital's portfolio value rose 12% quarter-over-quarter to $7.33B.

Based on Armistice Capital's 13F filing for Q4 2023, filed 13 Feb 2024.